These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 808449)

  • 1. [Effect of plasma and/or factor VIII concentrates administration on platelet functions in patients with haemophilia A and von Willebrand's disease (author's transl)].
    Gamba G; Grignani G; Nicolini E; Ascari E
    Haematologica; 1975 Jun; 60(2):168-83. PubMed ID: 808449
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing mild hemophilia A from von Willebrand's syndrome.
    Sabo MG; Triplett DA; Peden JC
    Am J Med Technol; 1978 May; 44(5):455-63. PubMed ID: 307909
    [No Abstract]   [Full Text] [Related]  

  • 5. [Von Willebrand's disease. Studies on platelet function, ristocetin induced platelet aggregation and factor VIII related antigen (author's transl)].
    Mimaya J; Nagao T; Iizuka A; Yamashita H
    Rinsho Ketsueki; 1975 Aug; 16(8):775-84. PubMed ID: 1081150
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of von Willebrand's Disease.
    Mannucci PM
    N Engl J Med; 2004 Aug; 351(7):683-94. PubMed ID: 15306670
    [No Abstract]   [Full Text] [Related]  

  • 7. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ; Rogers J; Brand H
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic studies in von Willebrand's disease: alteration of factor VIII/von Willebrand protein after transfusion with plasma concentrates in patients with von Willebrand's disease.
    Sultan Y; Simeon J; Maisonneuve P; Caen JP
    Thromb Haemost; 1976 Feb; 35(1):110-9. PubMed ID: 1085498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM; Janosević S
    Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 1973 look at hemophilia and von Willebrand's disease.
    Ratnoff OD
    Proc Inst Med Chic; 1973; 29(9):296-304. PubMed ID: 4581203
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of plasma fractions in the treatment of hemophilia and von Willebrand's disease.
    Rizza CR; Biggs R
    Prog Hematol; 1969; 6():181-200. PubMed ID: 4889322
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic effect of heat-treated factor VIII concentrates in von Willebrand's disease and related disorders: studies in platelet-type von Willebrand's disease].
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Takizawa S; Tamura M; Yamaguchi T; Wada K; Shibata A
    Rinsho Ketsueki; 1987 Dec; 28(12):2117-24. PubMed ID: 3133507
    [No Abstract]   [Full Text] [Related]  

  • 14. Progress and problems in hemophilia and von Willebrand's disease.
    Abildgaard CF
    Adv Pediatr; 1984; 31():137-77. PubMed ID: 6440429
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biological diagnosis of von Willebrand's disease (author's transl)].
    Castillo R; Maragall S; Liendo F; Ordinas A
    Sangre (Barc); 1978; 23(5B):728-45. PubMed ID: 310168
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of von Willebrand's disease.
    Mannucci PM
    J Intern Med Suppl; 1997; 740():129-32. PubMed ID: 9350194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII:C and VIII:CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma.
    Holmberg L; Borge L; Nilsson IM
    Br J Haematol; 1981 Apr; 47(4):587-96. PubMed ID: 6783063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand's disease--a common bleeding disorder.
    Lian EC
    Adv Intern Med; 1977; 22():207-28. PubMed ID: 320841
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(1):19-25. PubMed ID: 7796372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.